Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial–Mesenchymal Transition | Zendy

Jiejie Cai | Zendy; Xiaohong Chen | Zendy; Xingxing Chen | Zendy; Lingzhi Chen | Zendy; Gaoshu Zheng | Zendy; Hao Zhou | Zendy; Xi Zhou | Zendy

Open Access

Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial–Mesenchymal Transition

Author(s) -

Jiejie Cai,

Xiaohong Chen,

Xingxing Chen,

Lingzhi Chen,

Gaoshu Zheng,

Hao Zhou,

Xi Zhou

Publication year - 2017

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000464125

Subject(s) - relaxin , spironolactone , cardiac fibrosis , endocrinology , medicine , myocardial fibrosis , fibrosis , isoprenaline , transforming growth factor , chemistry , aldosterone , hormone , stimulation

The effect of relaxin and spironolactone combined on myocardial fibrosis has not been reported. Thus, we investigated the effect of the combined therapy on isoprenaline-induced myocardial fibrosis and the mechanism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research